Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate

Published 09/12/2021, 12:23
Updated 09/12/2021, 13:10
© Reuters.  Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate

© Reuters. Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate

  • Relmada Therapeutics (NASDAQ:RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross proceeds of approximately $150 million.
  • The offer price represents a discount of almost 8% from the last close price of $18.54 on Wednesday.
  • Earlier, the company offered to sell $100 million of shares.
  • The offering will close by December 13.
  • Underwriters have an option to purchase up to an additional 1.32 million shares.
  • Relmada will use the proceeds to fund R&D activities for its lead product candidate, REL-1017 (esmethadone), for depression and other potential indications.
  • Price Action: RLMD shares are down 2.91% at $18 during the premarket session on the last check Thursday.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.